WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.125

WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.125

Impact of ErbB mutations on clinical outcomes in afatinib- or erlotinib-treated patients with SqCC of the lung

Glenwood D. Goss, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Salih Guclu, Dolores Isla, Joo Min Young, Alessandro Morabito, Andrea Ardizzoni, Shirish M. Gadgeel, Neil Gibson, Nicole Krämer, Flavio Solca, Agnieszka Cseh, Eva Ehrnrooth, Jean-Charles Soria

1200.125 LL8 ERB WCLC 2017 Poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Soria JC, et al. Lancet Oncol 2015;16(8):897–907

New developments in the treatment of advanced squamous cell lung cancer: focus on Afatinib

Hirsh V. Onco Targets Ther. 2017 May 11;10:2513-2526

Second-line afatinib for advanced  squamous cell carcinoma of the lung:  analysis of afatinib long-term responders  in the Phase III LUX-Lung 8 trial

Goss G, et al. WCLC 2017: OA23.03

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

Felip E, et al. Clinical Lung Cancer, In press

Further information: PFS and OS curves

Goss GD, et al.WCLC 2017